Skip to Content
Link
Connecting medical imaging leaders to the latest industry news, best practices, and AHRA happenings.
AHRA
RADIOLOGY MANAGEMENT
IS NOW PART OF LINK!
  • Leadership & Workforce Management
  • Operational Excellence
  • Technology & Innovation
  • Patient Care
  • Regulatory & Compliance
  • Career Journey
  • Podcast
  • About
Bipartisan Proposal Would Modify Reimbursement for Newer Diagnostic Radiopharmaceuticals
Regulatory & Compliance Bipartisan Proposal Would Modify Reimbursement for Newer Diagnostic Radiopharmaceuticals June 12, 2023 - Branden Cordeiro
Share this story:

A bipartisan group of lawmakers in the House of Representatives and Senate have introduced legislation that would modify how Medicare reimburses providers for treatments using diagnostic radiopharmaceuticals (RPs). Currently, diagnostic RPs are packaged as “supplies” under the Hospital Outpatient Prospective Payment System (HOPPS).

The Facilitating Innovative Nuclear Diagnostics (FIND) Act would require CMS to adopt a separate payment policy under HOPPS for RPs brought to market after 2008 that exceed the cost of $500 per day. The current Medicare payment system averages the cost of newer and more costly RPs with more commonly used and less expensive versions of the treatments. Advocates, such as the Society of Nuclear Medicine & Molecular Imaging (SNMMI), argue that the current payment methodology for RPs limits access to the newer, more effective treatments for chronic diseases by incentivizing providers to choose the lower cost and potentially less effective treatments.

It is important to consider that the bill requires CMS to implement the new payment structure in a budget-neutral manner, meaning these changes would lead to reduced reimbursement for those lower cost Radiopharmaceuticals and potentially impact reimbursement in other areas of HOPPS.

This is the second iteration of the FIND Act, first introduced in the last Congress. SNMMI and other proponents are hoping that a grassroots effort across the imaging space could lead to a more successful outcome for the legislation this session.

It is unlikely that Congress will act on this as a stand-alone bill, but if proponents are able to emphasize the bill’s ability to control overall costs in the Medicare program and improve clinical outcomes for patients, it is not out of the realm of possibility that this proposal be included as a “policy-rider” in a year-end appropriations package.

AHRA has not formally taken a position on this legislation. However, if you are interested in contacting your federal representatives in Congress about this legislation, you can utilize SNMMI’s grassroots advocacy tool.

Please visit AHRA Advocacy for more information on regulatory issues, legislation, AUC, and more! This information was provided by Capitol Associates, AHRA's advocacy partner in Washington, DC.

Branden Cordeiro Capitol Associates, Inc.
Tags: AHRA News     Regulatory Review     Industry News

More from LINK

From Screening to Strategy: How Radiology Drives Downstream Revenue and Coordinated Care
Patient Care From Screening to Strategy: How Radiology Drives Downstream Revenue and Coordinated Care March 10, 2026 - Lisa Walling, CRA Learn More
New Podcast: From Capstone Project to Real Community Impact — Lisa Walling's Leaders of Choice Experience
Podcast New Podcast: From Capstone Project to Real Community Impact — Lisa Walling's Leaders of Choice Experience March 10, 2026 - Lisa Walling, CRA Learn More
From Console to Corner Office: Staying True to Where We Started
Career Journey From Console to Corner Office: Staying True to Where We Started March 09, 2026 - Serage M. Rahima, CRA Learn More
AHRA
AHRA: The Association for Medical Imaging Management

2001 K Street NW, Third Floor North, Washington, DC 20006
Tel: (800) 334-2472
Email: memberservices@ahra.org

Quick Links Press Releases
Volunteer
Privacy & Terms Terms of Use
Privacy
Login
Copyright AHRA. All Rights Reserved.